In order to determine the long-term associations of various levels of LDL-C with CVD-related mortality, researchers conducted a study involving 36,375 participants with low 10-year risk of atherosclerotic...
In a recent meta-analysis of 34 trials and more than 270,000 participants, the authors aimed to compare the effects of more and less intensive LDL-C lowering on both all-cause and cardiovascular-specific...
Previous evidence has linked high levels of HDL cholesterol to lower risk of heart disease, but recent studies have begun to question how good the “good” cholesterol actually is.
Although previous research has suggested that high variability in cholesterol levels may be associated with cardiovascular events in patients with coronary artery disease, it is unclear how it affects...
The long-term safety and efficacy of the cholesterol-lowering drug alirocumab have not yet been established. In a recent study, researchers assessed the effects of prolonged use of alirocumab compared with...
The ACC has updated its 2016 expert consensus decision pathway for the use of non-statin drugs for the lowering of LDL cholesterol in patients with atherosclerotic cardiovascular disease.
A recent study examined the efficacy of an experimental cholesteryl ester transfer protein inhibitor for lowering major adverse cardiovascular events in patients with high-risk vascular disease.
The American Association of Clinical Endocrinologists and the American College of Endocrinology have released new guidelines for the treatment and management of dyslipidemia and the prevention of...
